Recent Updates
Recently added Catalysts
APMD Positive Sentiment

Apnimed Appoints Experienced Pharmaceutical Executive Kevin R. Lind as Chief Executive Officer to Implement Next Phase of Growth Strategy

Monday, June 8, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Apnimed has appointed Kevin R. Lind as the new Chief Executive Officer, succeeding founder Lawrence G. Miller, MD, who will take on the role of Vice Chair of the Board. Mr. Lind brings extensive experience in the pharmaceutical industry, including leadership roles that have resulted in successful acquisitions. This leadership change is aimed at implementing the next phase of the company's growth strategy.

Market Sentiment Analysis

POSITIVE FACTORS

  • Appointment of an experienced CEO to drive growth.
  • Transitioning founder to a strategic role enhances leadership.
  • Mr. Lind's background includes successful acquisitions.

Full Press Release Details

Mr. Lind succeeds Company founder Lawrence G. Miller, MD, who is transitioning to Vice Chair of the Board Mr. Lind brings significant prior CEO, commercial, financial and capital markets experience, including leading Longboard Pharmaceuticals to an acquisition by H.

Frequently Asked Questions

Who is the new CEO of Apnimed?

Kevin R. Lind has been appointed as the new CEO of Apnimed.

What position will Lawrence G. Miller hold?

Lawrence G. Miller will transition to Vice Chair of the Board.

What experience does Kevin R. Lind bring?

Mr. Lind has significant experience in CEO roles and capital markets.

What is the goal of the leadership change?

The leadership change aims to implement the next phase of growth strategy.

ShareAdd on Google
Tags: APMD Apnimed Kevin R. Lind Lawrence G. Miller pharmaceutical executive leadership change
Last updated: Jun 8, 2026

Biotech snapshot

Cash runway
$173M liquidity · $4M/mo burn
~44 mo
Minimal dilution risk